Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium
A real-world research study to advance precision medicine for lung cancer
MYLUNG Consortium will observe approximately 12,000 community-based, non-small cell lung cancer (NSCLC) patients over a five-year period under the framework of one of the first broad, research endeavors in lung cancer.
The consortium marks an exceptional level of engagement among diverse organizations and stakeholders, working together across the spectrum of NSCLC therapy, drug development and care.
NSCLC is the most common type of lung cancer according to the American Cancer Society, accounting for about 84% of lung cancer cases.
This phase of the study examines data in structured fields of the EHR to discover trends such as the rate of testing, tests selected, and other practice patterns, and it lays the groundwork for the next two study protocols. This will help to uncover some of the unique challenges to molecular testing that providers and practices are facing.
PROTOCOL 2
This phase of the study focuses on how information is obtained, utilized and operationalized in decision-making. This will help to understand the types of patients presenting and the barriers to molecular testing across different types of practices with varying levels of expertise, not only in lung cancer, but also in molecular diagnostics.
PROTOCOL 3
The individual clinical trials will integrate findings from the previous protocols and explore new processes and associated outcomes. This will help to improve the rate of appropriate molecular testing and the subsequent assignment of indicated targeted therapies
2020
2021
2026
PROTOCOL 1
2023
2024
2025
By the numbers
2022
~3,500
Patients:
Time period:
2
years
By the numbers
Patients:
Practices:
~1,000
~10
Time period:
months
6-9
By the numbers
Patients:
Practices:
~7,500
~15
Time period:
years
5
A retrospective review of real-world data from Ontada’s iKnowMed electronic health records (EHRs) of patients treated by providers in The US Oncology Network.
SM
A prospective, observational trial to monitor the real-world patient journey from presentation through their first line of cancer therapy.
A platform upon which prospectively-assessed interventional strategies in patient-engagement algorithms will be conducted to help providers make the best treatment recommendations based on the data available.
An inside look at the
Learn more about the businesses powering the MYLUNG Consortium
In November 2022, McKesson and HCA Healthcare formed a joint venture combining Sarah Cannon Research Institute with US Oncology Research, the research arm of The US Oncology Network. The joint venture, named Sarah Cannon Research Institute, is a fully integrated oncology research organization aimed at expanding clinical research, accelerating drug development and increasing availability and access to clinical trials for community oncology providers and patients. The collaboration brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the U.S.
An oncology insights and technology business dedicated to transforming the fight against cancer. We support science through our data, technology and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients.
Learn more
Robert Coleman, MD
Program Principal Investigator
Chief Scientific Officer with US Oncology Research
Nicholas Robert, MD
Principal Investigator
Medical Director, Oncology Research & Insights with Ontada
Makenzi Evangelist, MD
Principal Investigator
Oncologist with New York Oncology Hematology
Participating sites
Illinois Cancer Specialists
Maryland Oncology Hematology
Minnesota Oncology
New York Oncology Hematology
Oncology Hematology Care
Amgen
Eli Lilly and Company
Mirati Therapeutics
A collaboration between:
Consortium
®
TM
®
Learn more
MYLUNG
PROTOCOL 1
PROTOCOL 2
PROTOCOL 3
AstraZeneca
Amgen
Eli Lilly and Company
Genentech
GO2 Foundation
LUNGevity
Mirati Therapeutics
®
A retrospective review of real-world data from Ontada’s iKnowMed electronic health records (EHRs) of patients treated by providers in The US Oncology Network.
SM
years
2
By the numbers
Patients:
~1,000
Sites:
12
Time period:
months
~21
Illinois Cancer Specialists
Maryland Oncology Hematology
Minnesota Oncology
New York Oncology Hematology
Oncology Hematology Care
Rocky Mountain Cancer Centers
Southern Cancer Center
Texas Oncology
Virginia Cancer Specialists
Virginia Oncology Associates
Willamette Valley Cancer Institute and Research Center
Woodlands Medical Specialists in Pensacola, FL
Janssen
GO2 Foundation
